Analyzing Atrion (ATRI) & Its Competitors

Atrion (NASDAQ: ATRI) is one of 79 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its peers? We will compare Atrion to similar companies based on the strength of its risk, earnings, valuation, analyst recommendations, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for Atrion and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrion 0 0 0 0 N/A
Atrion Competitors 280 1351 2800 102 2.60

As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 10.88%. Given Atrion’s peers higher possible upside, analysts clearly believe Atrion has less favorable growth aspects than its peers.


Atrion pays an annual dividend of $4.80 per share and has a dividend yield of 0.9%. Atrion pays out 26.6% of its earnings in the form of a dividend. As a group, “Medical Equipment, Supplies & Distribution” companies pay a dividend yield of 0.9% and pay out 30.5% of their earnings in the form of a dividend. Atrion has increased its dividend for 15 consecutive years. Atrion is clearly a better dividend stock than its peers, given its higher yield and lower payout ratio.

Insider and Institutional Ownership

58.8% of Atrion shares are owned by institutional investors. Comparatively, 66.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 23.1% of Atrion shares are owned by insiders. Comparatively, 12.6% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


This table compares Atrion and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atrion 22.98% 18.34% 16.33%
Atrion Competitors -125.71% -22.34% -10.15%

Earnings & Valuation

This table compares Atrion and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Atrion $143.49 million $27.58 million 30.24
Atrion Competitors $1.01 billion $74.51 million 228.03

Atrion’s peers have higher revenue and earnings than Atrion. Atrion is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Atrion has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Atrion’s peers have a beta of 0.94, meaning that their average stock price is 6% less volatile than the S&P 500.

About Atrion

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with's FREE daily email newsletter.

Leave a Reply